

**REGISTERED NUMBER: 10690411 (England and Wales)**

**Unaudited Financial Statements for the Year Ended 31 March 2019**

**for**

**JG Medical Consultancy Limited**

**Contents of the Financial Statements  
for the Year Ended 31 March 2019**

	<b>Page</b>
<b>Balance Sheet</b>	<b>1</b>
<b>Notes to the Financial Statements</b>	<b>3</b>

**JG Medical Consultancy Limited (Registered number: 10690411)**

**Balance Sheet**  
**31 March 2019**

	Notes	2019 £	2018 £
<b>FIXED ASSETS</b>			
Tangible assets	4	1,983	1,125
<b>CURRENT ASSETS</b>			
Debtors	5	34	1,493
Cash at bank		<u>7,745</u>	<u>1,228</u>
		7,779	2,721
<b>CREDITORS</b>			
Amounts falling due within one year	6	<u>(7,569)</u>	<u>(3,524)</u>
<b>NET CURRENT ASSETS/(LIABILITIES)</b>		<u>210</u>	<u>(803)</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		2,193	322
<b>PROVISIONS FOR LIABILITIES</b>		<u>(381)</u>	<u>(214)</u>
<b>NET ASSETS</b>		<u>1,812</u>	<u>108</u>
<b>CAPITAL AND RESERVES</b>			
Called up share capital	7	101	101
Retained earnings		<u>1,711</u>	<u>7</u>
<b>SHAREHOLDERS' FUNDS</b>		<u>1,812</u>	<u>108</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2019.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2019 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

The notes form part of these financial statements

**Balance Sheet - continued**  
**31 March 2019**

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 3 December 2019 and were signed by:

Dr J Galloway - Director

**Notes to the Financial Statements  
for the Year Ended 31 March 2019**

**1. COMPANY INFORMATION**

JG Medical Consultancy Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address are as below:

<b>Registered number:</b>	10690411
<b>Registered office:</b>	49 Peter Street Manchester M2 3NG

The presentation currency of the financial statements is the Pound Sterling (£).

**2. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Turnover**

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the provision of professional services is recognised on delivery of the service.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Tangible fixed assets are included at cost less depreciation and impairment. Depreciation has been computed to write off the cost of tangible fixed assets over their expected useful life.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Notes to the Financial Statements - continued  
for the Year Ended 31 March 2019**

**2. ACCOUNTING POLICIES - continued**

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

**3. EMPLOYEES AND DIRECTORS**

The average number of employees during the year was NIL (2018 - 1 ).

**4. TANGIBLE FIXED ASSETS**

	<b>Computer equipment £</b>
<b>COST</b>	
At 1 April 2018	1,500
Additions	<u>1,651</u>
At 31 March 2019	<u>3,151</u>
<b>DEPRECIATION</b>	
At 1 April 2018	375
Charge for year	<u>793</u>
At 31 March 2019	<u>1,168</u>
<b>NET BOOK VALUE</b>	
At 31 March 2019	<u>1,983</u>
At 31 March 2018	<u>1,125</u>

**5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2019 £</b>	<b>2018 £</b>
Directors' current accounts	<u>34</u>	<u>1,493</u>

**Notes to the Financial Statements - continued  
for the Year Ended 31 March 2019**

**6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2019</b>	<b>2018</b>
	<b>£</b>	<b>£</b>
Tax	6,571	2,888
Accrued expenses	998	636
	<u>7,569</u>	<u>3,524</u>

**7. CALLED UP SHARE CAPITAL**

**Allotted, issued and fully paid:**

<b>Number:</b>	<b>Class:</b>	<b>Nominal value:</b>	<b>2019</b>	<b>2018</b>
			<b>£</b>	<b>£</b>
100	A Ordinary Shares	1	100	100
1	B Ordinary Shares	1	1	1
			<u>101</u>	<u>101</u>

Ordinary A Shares confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

Ordinary B Shares do not confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

The A and B shares rank pari passu in terms of dividends and capital distribution rights.

**8. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES**

During the period the company operated a loan account with the director. At the balance sheet date Dr J Galloway owed JG Medical Consultancy Limited £34 (2018 - £1,494). This amount is included in other debtors, is repayable on demand and no interest was charged during the period.

Dividends totalling £8,450 were paid in the year in respect of shares held by the company's director.

**9. ULTIMATE CONTROLLING PARTY**

The ultimate controlling party is Dr J Galloway.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.